You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
During a case management conference last week, Premaitha said the EC's competition department contacted it regarding an investigation into Illumina and Sequenom.
In its court filing, the company said Twist Founder and CEO Emily LeProust stole its technology and breached her confidentiality agreements.
The company has sued three companies in the UK and two in Poland alleging they infringed on the firm's non-invasive prenatal testing patents.
Agilent will pay Enzo $9 million to settle the suit, which involved a US patent issued to Enzo and describing non-porous solid supports for nucleic acids.
The company exited the NGS whole-genome analysis market a few years ago and is now focused on building a business around its core IP search technology.
Hologic said in its Form 10-Q that Enzo sued the firm in March alleging infringement of a patent related to labeled nucleotides for use as diagnostic tools.
The appeals court reversed in part an earlier decision by aUSdistrict court that resulted in a $61 million award to Enzo, and remanded the case back to the district court.
Illumina and its subisidiary Verinata allege Premaitha's Iona test infringes two European patents relating to the use of cell-free fetal DNA for NIPT.
Several early-access customers presented results from the 10X technology at the meeting.
The IP covers the detection of histone modifications in cell-free nucleosomes from circulating cancer cells.
Retraction Watch writes that a cancer researcher has had an eighth paper retracted.
Computational biologist James Taylor has died, according to Johns Hopkins University.
The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.
In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.